The clinical trial process is a costly and integral part of bringing a drug to market, but does it have to be carried out the way it is currently? Is there a better way?
The process is well known to all of us in the industry, with Phase III being large-scale human trials in patients with the condition the drug is to treat, and then when enough of those respond successfully, it will likely gain approval.
The issue here is that the more we understand about how the body works, the more we realize that it is highly likely that many of the patients in the trial are not patients who have the condition.
Read More >>